Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Table 2 Clinical responses of third-generation EGFR-TKI as second line therapy in NSCLC patients with EGFR 19delins and EGFR 19del

CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease, ORR Objective response rate, DCR Disease control rate

ISSN: 1471-2407